| By Cindy Wu, Asia Manufacturing Pharma |
| Monday, 04 May 2009 |
 |
Although macrolides antibiotics, one of the most commonly-used antibiotics, had witnessed strong growth in China, sales decreased in recent years. The country’s recently launched new healthcare reform package is expected to have a positive impact on the pharmaceutical sector, including macrolides antibiotics. In 2008, the macrolides antibiotics market in China increased 4.20 percent to RMB3,839 million (approx US$560 million) from RMB3,684 million (approx US$538 million) in
|
|
the previous year, with a share of 4.05 percent of the entire anti-infective agents market, down from 5.03 percent in the previous year. |
|
|
Without support from new products, market share is likely to continue to shrink.
The top three best-selling macrolides antibiotics in the Chinese market were Azithromycin, Clarithromycin and Roxithromycin, with shares of 54.6 percent, 24.8 percent and 8.3 percent, respectively.
The strong growth has been led by Azithromycin, Clarithromycin, Roxithromycin and Erythromycin Ethylsuccinate, however, sales later decreased slightly due to the impact of intensified regulations, declining prices and implementation of prescribed drugs management measures. The expansion of basic medical insurance coverage, the establishment of a basic medicine |
|
system, and the building out of new rural cooperative medical services are expected to boost the expansion of these antibiotics.
With the opportunities brought about by the new healthcare reform package, sales of macrolides antibiotics are expected to increase significantly.
Want to read more?
Outlook for China's API sector remains optimistic, despite current challenges
Livzon Pharmaceutical Group delivered revenue of RMB 2.06 billion
Lunan Pharmaceutical unveils Gimeracil and Oteracil Porassium Capsules |
|
|
